Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Serum's Bilthoven acquisition opens door to cut-price polio vaccine in Europe and US

This article was originally published in Scrip

Executive Summary

Serum Institute's acquisition of the government-owned Dutch manufacturer of monoclonal antibodies and vaccines, Bilthoven Biologicals, is expected to change the market dynamics for injectable polio vaccines, the capability and technology for which is currently vested in just three global facilities. The buyout will also provide the Indian firm with a manufacturing foothold in the West, boosting its plans to expand into Europe and the US.

You may also be interested in...



Panacea-Serum Team Up To Take Six-In-One Vaccine Global

Panacea Biotec has allied with the world’s largest-vaccine maker, the Serum Institute of India, to ramp up production of a six-in-one jab aimed at preventing killer diseases like polio and diphtheria and target a global market estimated to be worth over $1.25bn annually.

Can Roche’s Phesgo Mirror UK Adoption Trend in India?

Roche debuts ‘responsibly priced’ Phesgo in India. Will the dramatic reduction in treatment time for women with HER2 positive breast cancer and other benefits, including insurance coverage, trigger sharp shifts towards the subcutaneous fixed-dose combination of Perjeta and Herceptin?

Alembic Remains Upbeat Despite Rhizen Setback

Disappointment for Alembic-backed Rhizen after partner TG Therapeutics takes Ukoniq off the US market amid wider regulatory scrutiny around the PI3K inhibitor class of drugs. The Indian firm, however, remains upbeat about the US business, which saw significant growth in the fiscal fourth quarter and has 15-plus launches lined up.

Topics

Related Companies

UsernamePublicRestriction

Register

SC018002

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel